Perceptive Advisors LLC lifted its stake in TESARO Inc (NASDAQ:TSRO) by 8.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 388,651 shares of the biopharmaceutical company’s stock after buying an additional 29,100 shares during the period. TESARO makes up 1.9% of Perceptive Advisors LLC’s portfolio, making the stock its 12th biggest position. Perceptive Advisors LLC owned 0.71% of TESARO worth $50,175,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other hedge funds and other institutional investors also recently modified their holdings of TSRO. Exane Derivatives acquired a new position in shares of TESARO in the third quarter worth about $106,000. Botty Investors LLC acquired a new position in shares of TESARO in the second quarter worth about $140,000. Nordea Investment Management AB acquired a new position in shares of TESARO in the second quarter worth about $167,000. Oppenheimer Asset Management Inc. raised its stake in TESARO by 3,042.6% during the second quarter. Oppenheimer Asset Management Inc. now owns 1,477 shares of the biopharmaceutical company’s stock valued at $206,000 after buying an additional 1,430 shares in the last quarter. Finally, Toronto Dominion Bank raised its stake in TESARO by 244.6% during the third quarter. Toronto Dominion Bank now owns 1,592 shares of the biopharmaceutical company’s stock valued at $206,000 after buying an additional 1,130 shares in the last quarter.
In related news, Director James O. Armitage sold 10,000 shares of the stock in a transaction that occurred on Monday, September 18th. The stock was sold at an average price of $117.13, for a total value of $1,171,300.00. Following the completion of the transaction, the director now directly owns 10,000 shares of the company’s stock, valued at approximately $1,171,300. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Martin H. Jr. Huber sold 592 shares of the stock in a transaction that occurred on Friday, September 22nd. The stock was sold at an average price of $118.60, for a total value of $70,211.20. Following the completion of the transaction, the senior vice president now directly owns 6,943 shares of the company’s stock, valued at $823,439.80. The disclosure for this sale can be found here. Insiders have sold 11,421 shares of company stock valued at $1,312,175 over the last ninety days. Corporate insiders own 40.50% of the company’s stock.
Several analysts have issued reports on TSRO shares. Barclays started coverage on TESARO in a research note on Monday, October 23rd. They set an “equal weight” rating and a $135.00 price objective on the stock. ValuEngine cut TESARO from a “hold” rating to a “sell” rating in a research note on Tuesday, October 10th. HC Wainwright restated a “buy” rating and set a $158.00 price objective on shares of TESARO in a research note on Thursday, October 26th. Jefferies Group restated a “hold” rating and set a $124.00 price objective on shares of TESARO in a research note on Friday, November 3rd. Finally, Morgan Stanley restated an “overweight” rating and set a $165.00 price objective (down previously from $181.00) on shares of TESARO in a research note on Wednesday, November 8th. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. TESARO has an average rating of “Buy” and a consensus price target of $159.39.
TESARO Inc (NASDAQ TSRO) opened at $84.39 on Friday. TESARO Inc has a fifty-two week low of $79.03 and a fifty-two week high of $192.94. The company has a current ratio of 4.73, a quick ratio of 4.35 and a debt-to-equity ratio of 0.34.
TESARO (NASDAQ:TSRO) last posted its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.47) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.16) by $0.69. The company had revenue of $142.77 million during the quarter, compared to analyst estimates of $130.57 million. TESARO had a negative return on equity of 93.39% and a negative net margin of 251.22%. The business’s revenue was up 740.3% compared to the same quarter last year. During the same period in the prior year, the company earned ($1.72) earnings per share. equities analysts predict that TESARO Inc will post -8.17 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Perceptive Advisors LLC Has $50.18 Million Stake in TESARO Inc (TSRO)” was first reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece of content can be read at https://ledgergazette.com/2017/12/10/perceptive-advisors-llc-has-50-18-million-stake-in-tesaro-inc-tsro.html.
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Receive News & Ratings for TESARO Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc and related companies with MarketBeat.com's FREE daily email newsletter.